Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
Clinical trial NCT06762327 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06762327
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-28
- Primary completion
- 2026-12-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.